These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
600 related articles for article (PubMed ID: 25423180)
1. Nanomaterials for theranostics: recent advances and future challenges. Lim EK; Kim T; Paik S; Haam S; Huh YM; Lee K Chem Rev; 2015 Jan; 115(1):327-94. PubMed ID: 25423180 [No Abstract] [Full Text] [Related]
2. Nanomedicine transforms drug delivery. Shaffer C Drug Discov Today; 2005 Dec; 10(23-24):1581-2. PubMed ID: 16376810 [No Abstract] [Full Text] [Related]
3. Nanomedicine for cancer: lipid-based nanostructures for drug delivery and monitoring. Namiki Y; Fuchigami T; Tada N; Kawamura R; Matsunuma S; Kitamoto Y; Nakagawa M Acc Chem Res; 2011 Oct; 44(10):1080-93. PubMed ID: 21786832 [TBL] [Abstract][Full Text] [Related]
4. Nanomedicine and drug delivery. Wei C; Wei W; Morris M; Kondo E; Gorbounov M; Tomalia DA Med Clin North Am; 2007 Sep; 91(5):863-70. PubMed ID: 17826106 [TBL] [Abstract][Full Text] [Related]
5. Bioinspired approaches for cancer nanotheranostics. Evangelopoulos M; Tasciotti E Nanomedicine (Lond); 2017 Jan; 12(1):5-7. PubMed ID: 27876435 [No Abstract] [Full Text] [Related]
6. Nanotechnology platforms and physiological challenges for cancer therapeutics. Kim KY Nanomedicine; 2007 Jun; 3(2):103-10. PubMed ID: 17442621 [TBL] [Abstract][Full Text] [Related]
7. Emerging advances in nanomedicine with engineered gold nanostructures. Webb JA; Bardhan R Nanoscale; 2014 Mar; 6(5):2502-30. PubMed ID: 24445488 [TBL] [Abstract][Full Text] [Related]
8. DNA nanostructure-based imaging probes and drug carriers. Zhan P; Jiang Q; Wang ZG; Li N; Yu H; Ding B ChemMedChem; 2014 Sep; 9(9):2013-20. PubMed ID: 25045126 [TBL] [Abstract][Full Text] [Related]
9. Biomedical nanotechnology for cancer. Pope-Harman A; Cheng MM; Robertson F; Sakamoto J; Ferrari M Med Clin North Am; 2007 Sep; 91(5):899-927. PubMed ID: 17826110 [TBL] [Abstract][Full Text] [Related]
10. Nanomedicines Targeting the Tumor Microenvironment. Tong R; Langer R Cancer J; 2015; 21(4):314-21. PubMed ID: 26222084 [TBL] [Abstract][Full Text] [Related]
11. Lanthanide-doped hollow nanomaterials as theranostic agents. Kang X; Li C; Cheng Z; Ma P; Hou Z; Lin J Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2014; 6(1):80-101. PubMed ID: 24227795 [TBL] [Abstract][Full Text] [Related]
12. Theranostic applications of carbon nanomaterials in cancer: Focus on imaging and cargo delivery. Chen D; Dougherty CA; Zhu K; Hong H J Control Release; 2015 Jul; 210():230-45. PubMed ID: 25910580 [TBL] [Abstract][Full Text] [Related]
13. Nanocarriers as an emerging platform for cancer therapy. Peer D; Karp JM; Hong S; Farokhzad OC; Margalit R; Langer R Nat Nanotechnol; 2007 Dec; 2(12):751-60. PubMed ID: 18654426 [TBL] [Abstract][Full Text] [Related]
14. A review: Integrin alphavbeta3-targeted molecular imaging and therapy in angiogenesis. Lim EH; Danthi N; Bednarski M; Li KC Nanomedicine; 2005 Jun; 1(2):110-4. PubMed ID: 17292065 [No Abstract] [Full Text] [Related]
15. Perspectives and advancements in the design of nanomaterials for targeted cancer theranostics. Tan YY; Yap PK; Xin Lim GL; Mehta M; Chan Y; Ng SW; Kapoor DN; Negi P; Anand K; Singh SK; Jha NK; Lim LC; Madheswaran T; Satija S; Gupta G; Dua K; Chellappan DK Chem Biol Interact; 2020 Sep; 329():109221. PubMed ID: 32768398 [TBL] [Abstract][Full Text] [Related]